BenevolentAI and baricitinib
An AI-driven knowledge graph that early flagged baricitinib as a possible treatment for severe COVID-19.
About
At the start of the pandemic, BenevolentAI linked biomedical literature and databases and proposed the existing rheumatoid arthritis drug baricitinib as a candidate. Researchers published the hypothesis and clinical studies then tested it. Those studies, not the model itself, provided the evidence of efficacy in certain groups of hospitalized COVID patients.
AI factor
Scientists assess which connections are biologically plausible and testable. The AI organizes large amounts of existing knowledge and helps surface unexpected candidates; laboratory research and clinical trials determine whether such a candidate actually works and is safe.
Sources
Inspiration sourced from AI For Good. Not an Arnaldus customer case.